O6-Benzylguanine (BG) and Temozolomide (TMZ) Therapy of Glioblastoma Multiforme (GBM) With Infusion of Autologous P140KMGMT+ Hematopoietic Progenitors to Protect Hematopoiesis.

Trial Profile

O6-Benzylguanine (BG) and Temozolomide (TMZ) Therapy of Glioblastoma Multiforme (GBM) With Infusion of Autologous P140KMGMT+ Hematopoietic Progenitors to Protect Hematopoiesis.

Suspended
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2016

At a glance

  • Drugs LG 631 (Primary) ; Benzylguanine; Temozolomide; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Dec 2016 Status changed from recruiting to suspended.
    • 18 Apr 2016 Planned number of patients changed from 18 to 14 as per ClinicalTrials.gov record.
    • 28 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top